Anixa Biosciences shares surge 11.89% premarket ahead of Water Tower Research fireside chat on breast cancer vaccine Phase 1 data and protein strategy.

Anixa Biosciences surged 11.89% in premarket trading following the announcement that its CEO will present final Phase 1 breast cancer vaccine trial data at a Water Tower Research Fireside Chat on December 15, 2025. The event, open to investors, will discuss the trial’s outcomes presented at the San Antonio Breast Cancer Symposium, the company’s "retired protein" vaccine strategy, and next steps in development. These updates highlight progress in Anixa’s pipeline, particularly its breast cancer vaccine licensed from Cleveland Clinic, and underscore partnerships with leading institutions like Moffitt Cancer Center. Positive investor sentiment likely stems from the anticipated validation of clinical-stage therapies and the company’s innovative approach to cancer immunotherapy, aligning with the premarket rally.